GLP1R and type 2 diabetes mellitus: Because the insulinotropic effect of GLP‐1 remains active under hyperglycaemic conditions in type 2 diabetes, various DPP‐4‐inhibitors that prolong GLP‐1 activity are now in clinical use as antidiabetic drugs that act to increase postprandial insulin action 7, 8.